NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $23.24 -1.21 (-4.95%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$22.92 -0.31 (-1.36%) As of 10/2/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tango Therapeutics Stock (NASDAQ:TNGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tango Therapeutics alerts:Sign Up Key Stats Today's Range$23.09▼$25.0950-Day Range$21.75▼$29.3652-Week Range$6.69▼$34.39Volume5.25 million shsAverage Volume3.04 million shsMarket Capitalization$3.92 billionP/E RatioN/ADividend YieldN/APrice Target$43.46Consensus RatingModerate Buy Company Overview Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities and activate the immune system against tumors. The company uses functional genomics, including CRISPR-based screening, to identify genetic dependencies that may be selectively targeted in cancer cells while limiting effects on healthy tissue. Tango’s research and development programs include small-molecule therapies and immuno-oncology candidates designed to address genetically defined cancers. Its pipeline has included programs targeting MAT2A and other cancer-related pathways, as well as approaches intended to enhance the ability of T cells to recognize and destroy tumor cells. Headquartered in Boston, Massachusetts, Tango Therapeutics was founded in 2017 and has collaborated with Gilead Sciences on the discovery and development of cancer immunotherapies. The company is led by President and Chief Executive Officer Barbara Weber, M.D., and primarily serves the global biopharmaceutical and oncology markets through its research, clinical development and strategic partnerships.AI Generated. May Contain Errors. Read More Tango Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreTNGX MarketRank™: Tango Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 544th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTango Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTango Therapeutics has a consensus price target of $43.46, representing about 87.0% upside from its current price of $23.24.Amount of Analyst CoverageTango Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tango Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -27.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -27.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.56% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 18.76, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently decreased by 1.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.26 News SentimentTango Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tango Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,604.00 in company stock.Percentage Held by Insiders6.50% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNGX Stock News HeadlinesHead-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) versus Tango Therapeutics (NASDAQ:TNGX)September 30, 2026 | americanbankingnews.comComparing Tango Therapeutics (NASDAQ:TNGX) and Syndax Pharmaceuticals (NASDAQ:SNDX)September 28, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 4 at 1:00 AM | Altimetry (Ad)Tango Therapeutics, Inc. (TNGX)September 27, 2026 | finance.yahoo.comIl principale responsabile contabile di Tango Therapeutics vende azioni per $198kSeptember 25, 2026 | it.investing.comTango Therapeutics (NASDAQ:TNGX) Insider Jessica Newcomb Sells 8,200 Shares of StockSeptember 25, 2026 | insidertrades.comTango Therapeutics (NASDAQ:TNGX) Shares Up 6% - What's Next?September 24, 2026 | americanbankingnews.comTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comSee More Headlines TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $8.86 at the start of the year. Since then, TNGX shares have increased by 162.3% and is now trading at $23.24. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.05. When did Tango Therapeutics IPO? Tango Therapeutics (TNGX) raised $145 million in an initial public offering (IPO) on Thursday, September 3rd 2020. The company issued 14,500,000 shares at $10.00 per share. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tango Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/11/2026Today10/04/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TNGX's financial health is in the Green zone, according to TradeSmith. TNGX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TNGX CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees137Year Founded2017Price Target and Rating Average Price Target for Tango Therapeutics$43.46 High Price Target$69.00 Low Price Target$14.00 Potential Upside/Downside+87.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$101.59 million Net MarginsN/A Pretax Margin-230.03% Return on Equity-25.75% Return on Assets-23.36% Debt Debt-to-Equity RatioN/A Current Ratio50.82 Quick Ratio50.82 Sales & Book Value Annual Sales$62.38 million Price / Sales62.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book9.04Miscellaneous Outstanding Shares168,610,000Free Float157,650,000Market Cap$3.92 billion OptionableOptionable Beta1.17 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:TNGX) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
